



US008741963B2

(12) **United States Patent**
Hiestand et al.

(10) **Patent No.:** **US 8,741,963 B2**
(45) **Date of Patent:** **Jun. 3, 2014**

(54) **S1P RECEPTOR MODULATORS FOR
TREATING MULTIPLE SCLEROSIS**

(75) Inventors: **Peter C. Hiestand**, Allschwil (CH);
Christian Schnell, Héisingue (FR)

(73) Assignee: **Novartis AG**, Basel (CH)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 21 days.

(21) Appl. No.: **13/149,468**

(22) Filed: **May 31, 2011**

(65) **Prior Publication Data**

US 2011/0237682 A1 Sep. 29, 2011

Related U.S. Application Data

(63) Continuation of application No. 12/303,765, filed as
application No. PCT/EP2007/005597 on Jun. 25,
2007, now abandoned.

(30) **Foreign Application Priority Data**

Jun. 27, 2006 (GB) 0612721.1

(51) **Int. Cl.**
A61K 31/13 (2006.01)

(52) **U.S. Cl.**
USPC **514/667**; 514/903

(58) **Field of Classification Search**
USPC 514/667, 903
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2006/0046979 A1 3/2006 Foster et al.

FOREIGN PATENT DOCUMENTS

WO WO 03/097028 11/2003
WO WO 03/099192 12/2003
WO WO 2004/028521 4/2004

WO WO 2004/050073 6/2004
WO WO 2004/113330 12/2004
WO WO 2005/123104 12/2005
WO WO 2006/055809 5/2006
WO WO 2006/058316 6/2006
WO WO 2006/066086 6/2006

OTHER PUBLICATIONS

Brinkmann, Volker et al., "The Immune Modulator FTY720 Targets
Sphingosine 1-Phosphate Receptors", The Journal of Biological
Chemistry, vol. 277, No. 24, Issue of Jun. 14, pp. 21453-21457,
(2002).

Miller et al., *Neurol. & Neurosci. Reports*, (Sep. 2010), 1095), pp.
397-406.

Hla, T., *FASEB Journal*, (Mar. 6, 2006), 20(4), part 1, A20.

LaMontagne K. „Antagonism of Sphingosine-1-Phosphate Recep-
tors by FTY720 Inhibits Angiogenesis.. *Cancer Research*, Jan. 2006,
66, 221-231.

Hla. T. „Physiological and pathological actions of sphingosine
1-phosphate Seminars in Cell & Developmental Biology, Oct. 2004,
15(5), 513-520.

Kappos I. et al. „FTY720 in relapsing MS . . . Jun. 23, 2005 online
(found Jun. 2, 2011) URL:[http://www.ms-in-europe.com/printver-
sion/index.php?anr=105&cnr=4/](http://www.ms-in-europe.com/printversion/index.php?anr=105&cnr=4/)>.

Ho J.W. et al. „ Effects of a novel immunomodulating agent . . .
Molecular cancer therapeutics, 2005 Set, 4(9), 1430-1438.

Virely D.J. "Developing therapeutics for the treatment of multiple
sclerosis." *Journal of American Society for Experimental Neuro
Therapeutics*. Oct. 2005, 2, 638-649. [http://pubget.com/paper/
16489371](http://pubget.com/paper/16489371).

Fujino et al. 'Amelioration of experimental autoimmune
encephalomyelitis . . . ' *The Journal of Pharmacology and Exper-
imental Therapeutics*, vol. 305, No. 1, pp. 70-77, 2003.

K. Rammohan et al, Poster on 'Long-Term Safety of Fingolimod in
Patients with Relapsing-Remitting Multiple Sclerosis: Results from
Phase 3 FREEDOMS II Extension Study' Mar. 16-23, 2013, San
Diego, US, 65th American Academy of Neurology Annual Meeting.

Primary Examiner — Kevin E Weddington

(74) *Attorney, Agent, or Firm* — Andrew Holmes

(57) **ABSTRACT**

The present invention relates to the use of the S1P receptor
modulator 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-
diol, administered at a daily dosage of 0.5 mg, for inhibiting
or treating neo-angiogenesis associated with multiple sclero-
sis.

9 Claims, No Drawings

1


S1P RECEPTOR MODULATORS FOR TREATING MULTIPLE SCLEROSIS

This application is a Continuation of U.S. application Ser. No. 12/303,765 filed Dec. 8, 2008 which is a 371 of PCT/EP2007/005597 filed on Jun. 25, 2007, which claims benefit of Great Britain Application No. 0612721.1 filed on Jun. 27, 2006, which in their entirety are herein incorporated by reference.


The present invention relates to the use of an S1P receptor modulator in the treatment or prevention of neo-angiogenesis associated with a demyelinating disease, e.g. multiple sclerosis.

S1P receptor modulators are typically sphingosine analogues, such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e.g. a compound comprising a group of formula X.

Sphingosine-1 phosphate (hereinafter "S1P") is a natural serum lipid. Presently there are eight known S1P receptors, namely S1P1 to S1P8. S1P receptor modulators are typically sphingosine analogues, such as 2-substituted 2-amino-propane-1,3-diol or 2-amino-propanol derivatives, e.g. a compound comprising a group of formula X



wherein Z is H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, phenyl, phenyl substituted by OH, C₁₋₆alkyl substituted by 1 to 3 substituents selected from the group consisting of halogen, C₃₋₈cycloalkyl, phenyl and phenyl substituted by OH, or CH₂—R_{4z} wherein R_{4z} is OH, acyloxy or a residue of formula (a)



wherein Z₁ is a direct bond or O, preferably O; each of R_{5z} and R_{6z}, independently, is H, or C₁₋₄alkyl optionally substituted by 1, 2 or 3 halogen atoms; R_{1z} is OH, acyloxy or a residue of formula (a); and each of R_{2z} and R_{3z} independently, is H, C₁₋₄alkyl or acyl.

Group of formula X is a functional group attached as a terminal group to a moiety which may be hydrophilic or lipophilic and comprise one or more aliphatic, alicyclic, aromatic and/or heterocyclic residues, to the extent that the resulting molecule wherein at least one of Z and R_{1z} is or comprises a residue of formula (a), signals as an agonist at one of more sphingosine-1-phosphate receptor.

S1P receptor modulators are compounds which signal as agonists at one or more sphingosine-1 phosphate receptors, e.g. S1P1 to S1P8. Agonist binding to a S1P receptor may e.g. result in dissociation of intracellular heterotrimeric G-proteins into Gα-GTP and Gβγ-GTP, and/or increased phosphorylation of the agonist-occupied receptor and activation of downstream signaling pathways/kinases.

The binding affinity of S1P receptor modulators to indi-

2

S1P receptor modulator activities of compounds are tested on the human S1P receptors S1P₁, S1P₂, S1P₃, S1P₄ and S1P₅. Functional receptor activation is assessed by quantifying compound induced GTP [γ -³⁵S] binding to membrane protein prepared from transfected CHO or RH7777 cells stably expressing the appropriate human S1P receptor. The assay technology used is SPA (scintillation proximity based assay). Briefly, DMSO dissolved compounds are serially diluted and added to SPA-bead (Amersham-Pharmacia) immobilised S1P receptor expressing membrane protein (10-20 μg/well) in the presence of 50 mM Hepes, 100 mM NaCl, 10 mM MgCl₂, 10 μM GDP, 0.1% fat free BSA and 0.2 nM GTP [γ -³⁵S] (1200 Ci/mmol). After incubation in 96 well microtiterplates at RT for 120 min, unbound GTP [γ -³⁵S] is separated by a centrifugation step. Luminescence of SPA beads triggered by membrane bound GTP [γ -³⁵S] is quantified with a TOPcount plate reader (Packard). EC₅₀s are calculated using standard curve fitting software. In this assay, the S1P receptor modulators preferably have a binding affinity to S1P receptor <50 nM.


Preferred S1P receptor modulators are e.g. compounds which in addition to their S1P binding properties also have accelerating lymphocyte homing properties, e.g. compounds which elicit a lymphopenia resulting from a re-distribution, preferably reversible, of lymphocytes from circulation to secondary lymphatic tissue, without evoking a generalized immunosuppression. Naïve cells are sequestered; CD4 and CD8 T-cells and B-cells from the blood are stimulated to migrate into lymph nodes (LN) and Peyer's patches (PP).

The lymphocyte homing property may be measured in following Blood Lymphocyte Depletion assay:

A S1P receptor modulator or the vehicle is administered orally by gavage to rats. Tail blood for hematological monitoring is obtained on day -1 to give the baseline individual values, and at 2, 6, 24, 48 and 72 hours after application. In this assay, the S1P receptor agonist or modulator depletes peripheral blood lymphocytes, e.g. by 50%, when administered at a dose of e.g. <20 mg/kg.

Examples of appropriate S1P receptor modulators are, for example:

Compounds as disclosed in EP627406A1, e.g. a compound of formula I



wherein R₁ is a straight- or branched (C₁₂₋₂₂) chain

which may have in the chain a bond or a hetero atom selected from a double bond, a triple bond, O, S, NR₆, wherein R₆ is H, C₁₋₄alkyl, aryl-C₁₋₄alkyl, acyl or (C₁₋₄alkoxy)carbonyl, and carbonyl, and/or

which may have as a substituent C₁₋₄alkoxy, C₂₋₄alkenyl, C₂₋₄alkynyl, acyl, C₁₋₄alkylamino, C₁₋₄alkylthio, acylamino, (C₁₋₄alkoxy)carbonyl, (C₁₋₄alkoxy)-carbonylamino, acyloxy, (C₁₋₄alkyl)

3

R₁ is

a phenylalkyl wherein alkyl is a straight- or branched (C₆₋₂₀) carbon chain; or

a phenylalkyl wherein alkyl is a straight- or branched (C₁₋₃₀) carbon chain wherein said phenylalkyl is substituted by

a straight- or branched (C₆₋₂₀) carbon chain optionally substituted by halogen,

a straight- or branched (C₆₋₂₀) alkoxy chain optionally substituted by halogen,

a straight- or branched (C₆₋₂₀) alkenyloxy, phenyl-C₁₋₄alkoxy, halophenyl-C₁₋₄alkoxy, phenyl-C₁₋₄alkoxy-C₁₋₄alkyl, phenoxy-C₁₋₄alkoxy or phenoxy-C₁₋₄alkyl,

cycloalkylalkyl substituted by C₆₋₂₀alkyl,

heteroarylalkyl substituted by C₆₋₂₀alkyl,

heterocyclic C₆₋₂₀alkyl or

heterocyclic alkyl substituted by C₂₋₂₀alkyl,

and wherein


the alkyl moiety may have

in the carbon chain, a bond or a heteroatom selected from a double bond, a triple bond, O, S, sulfinyl, sulfonyl, or NR₆, wherein R₆ is as defined above, and

as a substituent C₁₋₄alkoxy, C₂₋₄alkenyloxy, C₂₋₄alkynyl, arylC₁₋₄alkoxy, acyl, C₁₋₄alkylamino, C₁₋₄alkylthio, acylamino, (C₁₋₄alkoxy)carbonyl, (C₁₋₄alkoxy)carbonylamino, acyloxy, (C₁₋₄alkyl)carbamoyl, nitro, halogen, amino, hydroxy or carboxy, and

each of R₂, R₃, R₄ and R₅, independently, is H, C₁₋₄ alkyl or acyl or a pharmaceutically acceptable salt or hydrate thereof;


Compounds as disclosed in EP 1002792A1, e.g. a compound of formula II



wherein m is 1 to 9 and each of R'₂, R'₄ and R'₅, independently, is H, C₁₋₆alkyl or acyl,

or a pharmaceutically acceptable salt or hydrate thereof;

Compounds as disclosed in EP0778263 A1, e.g. a compound of formula III



wherein W is H; C₁₋₆alkyl, C₂₋₆alkenyl or C₂₋₆alkynyl; unsubstituted or by OH substituted phenyl; R''₄O(CH₂)_n; or C₁₋₆alkyl substituted by 1 to 3 substituents selected from the group consisting of halogen, C₃₋₈cycloalkyl, phenyl and phenyl substituted by OH;

X is H or unsubstituted or substituted straight chain alkyl having a number p of carbon atoms or unsubstituted or substituted straight chain alkoxy having a number (p-1) of carbon atoms, e.g. substituted by 1 to 3 substituents selected from the group consisting of C₁₋₆alkyl, OH, C₁₋₆alkoxy, acyloxy, amino, C₁₋₆alkylamino, acylamino, oxo, haloC₁₋₆alkyl,


4

OH, C₁₋₆alkoxy, acyl, acyloxy, amino, C₁₋₆alkylamino, acylamino, haloC₁₋₆alkyl and halogen; Y is H, C₁₋₆alkyl, OH, C₁₋₆alkoxy, acyl, acyloxy, amino, C₁₋₆alkylamino, acylamino, haloC₁₋₆alkyl or halogen, Z₂ is a single bond or a straight chain alkylene having a number or carbon atoms of q, each of p and q, independently, is an integer of 1 to 20, with the proviso of 6 ≤ p+q ≤ 23, m' is 1, 2 or 3, n is 2 or 3,


each of R''₁, R''₂, R''₃ and R''₄, independently, is H, C₁₋₄alkyl or acyl,

or a pharmaceutically acceptable salt or hydrate thereof,

Compounds as disclosed in WO02/18395, e.g. a compound of formula IVa or IVb




or



wherein X, is O, S, NR_{1s} or a group —(CH₂)_{n_a}—, which group is unsubstituted or substituted by 1 to 4 halogen; n_a is 1 or 2, R_{1s} is H or (C₁₋₄)alkyl, which alkyl is unsubstituted or substituted by halogen; R_{1a} is H, OH, (C₁₋₄)alkyl or O(C₁₋₄)alkyl wherein alkyl is unsubstituted or substituted by 1 to 3 halogen; R_{1b} is H, OH or (C₁₋₄)alkyl, wherein alkyl is unsubstituted or substituted by halogen; each R_{2a} is independently selected from H or (C₁₋₄)alkyl, which alkyl is unsubstituted or substituted by halogen; R_{3a} is H, OH, halogen or O(C₁₋₄)alkyl wherein alkyl is unsubstituted or substituted by halogen; and R_{3b} is H, OH, halogen, (C₁₋₄)alkyl wherein alkyl is unsubstituted or substituted by hydroxy, or O(C₁₋₄)alkyl wherein alkyl is unsubstituted or substituted by halogen; Y_a is —CH₂—, —C(O)—, —CH(OH)—, —C(=NOH)—, O or S, and R_{4a} is (C₄₋₁₄)alkyl or (C₄₋₁₄)alkenyl;

or a pharmaceutically acceptable salt or hydrate thereof;


Compounds as disclosed in WO02/06268A1, e.g. a compound of formula V



V

5

$R_{3,d}$ is hydrogen, a hydroxy-protecting group or a residue of formula



$R_{4,d}$ is C_{1-4} alkyl;

n_d is an integer of 1 to 6;

X_d is ethylene, vinylene, ethynylene, a group having a formula $-D-CH_2-$ (wherein D is carbonyl, $-CH(OH)-$, O, S or N), aryl or aryl substituted by up to three substituents selected from group a as defined hereinafter;

Y_d is single bond, C_{1-10} alkylene, C_{1-10} alkylene which is substituted by up to three substituents selected from groups a and b, C_{1-10} alkylene having O or S in the middle or end of the carbon chain, or C_{1-10} alkylene having O or S in the middle or end of the carbon chain which is substituted by up to three substituents selected from groups a and b;

$R_{5,d}$ is hydrogen, C_{3-6} cycloalkyl, aryl, heterocyclic group, C_{3-6} cycloalkyl substituted by up to three substituents selected from groups a and b, aryl substituted by up to three substituents selected from groups a and b, or heterocyclic group substituted by up to three substituents selected from groups a and b;


each of $R_{6,d}$ and $R_{7,d}$, independently, is H or a substituent selected from group a;

each of $R_{8,d}$ and $R_{9,d}$, independently, is H or C_{1-4} alkyl optionally substituted by halogen;

<group a> is halogen, lower alkyl, halogeno lower alkyl, lower alkoxy, lower alkylthio, carboxyl, lower alkoxy-carbonyl, hydroxy, lower aliphatic acyl, amino, mono-lower alkylamino, di- C_{1-4} alkylamino, acylamino, cyano or nitro; and <group b> is C_{3-6} cycloalkyl, aryl or heterocyclic group, each being optionally substituted by up to three substituents selected from group a;

with the proviso that when $R_{5,d}$ is hydrogen, Y_d is a either a single bond or linear C_{1-10} alkylene, or a pharmacologically acceptable salt, ester or hydrate thereof;


Compounds as disclosed in JP-14316985 (JP2002316985), e.g. a compound of formula VI



wherein $R_{1,e}$, $R_{2,e}$, $R_{3,e}$, $R_{4,e}$, $R_{6,e}$, $R_{7,e}$, n_e , X_e and Y_e are as disclosed in JP-14316985;

or a pharmacologically acceptable salt, ester or hydrate thereof;

Compounds as disclosed in WO03/062252A1, e.g. a compound of formula VII




VII

wherein

Ar is phenyl or naphthyl; each of m_g and n_g independently is 0 or 1; A is selected from COOH, PO_3H_2 , PO_2H , SO_3H , $PO(C_{1-3}alkyl)OH$ and 1H-tetrazol-5-yl; each of $R_{1,g}$ and $R_{2,g}$ independently is H, halogen, OH, COOH or C_{1-4} alkyl optionally substituted by halogen; $R_{3,g}$ is H or C_{1-4} alkyl optionally substituted by halogen or OH; each $R_{4,g}$ independently is halogen, or optionally halogen substituted C_{1-4} alkyl or C_{1-3} alkoxy; and each of R_g and M has one of the significances as indicated for B and C, respectively, in WO03/062252A1; or a pharmacologically acceptable salt, solvate or hydrate thereof;

Compounds as disclosed in WO 03/062248A2, e.g. a compound of formula VIII




VIII


wherein Ar is phenyl or naphthyl; n is 2, 3 or 4; A is COOH, 1H-tetrazol-5-yl, PO_3H_2 , PO_2H_2 , $-SO_3H$ or $PO(R_{5h})OH$ wherein R_{5h} is selected from C_{1-4} alkyl, hydroxy- C_{1-4} alkyl, phenyl, $-CO-C_{1-3}$ alkoxy and $-CH(OH)$ -phenyl wherein said phenyl or phenyl moiety is optionally substituted; each of $R_{1,h}$ and $R_{2,h}$ independently is H, halogen, OH, COOH, or optionally halogeno substituted C_{1-6} alkyl or phenyl; $R_{3,h}$ is H or C_{1-4} alkyl optionally substituted by halogen and/OH; each $R_{4,h}$ independently is halogeno, OH, COOH, C_{1-4} alkyl, $S(O)_{0,1}$ or C_{1-3} alkyl, C_{1-3} alkoxy, C_{3-6} cycloalkoxy, aryl or aralkoxy, wherein the alkyl portions may optionally be substituted by 1-3 halogens; and each of R_h and M has one of the significances as indicated for B and C, respectively, in WO03/062248A2

or a pharmacologically acceptable salt, solvate or hydrate thereof.

Compounds as disclosed in WO 04/103306A, WO 05/000833, WO 05/103309 or WO 05/113330, e.g. compounds of formula IXa or IXb



IXa



IXb

wherein

A_k is $COOR_{5k}$, $OPO(OR_{5k})_2$, $PO(OR_{5k})_2$, SO_2OR_{5k} , $POR_{5k}OR_{5k}$ or 1H-tetrazol-5-yl, R_{5k} being H or C_{1-6} alkyl; W_k is a bond, C_{3-9} alkylene or C_{2-3} alkenylene; Y_k is C_{6-10} aryl or C_{3-9} heteroaryl, optionally substituted by 1 to 3 radicals selected from halogeno, OH, NO_2 , C_{1-6} alkoxy; halo-substituted C_{1-6} alkyl and halo-substituted C_{1-6} alkoxy,

7

R_{1k} is C_{6-10} aryl or C_{3-9} heteroaryl, optionally substituted by C_{1-6} alkyl, C_{6-10} aryl C_{1-4} alkyl, C_{3-9} heteroaryl, C_{3-9} heteroaryl C_{1-4} alkyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl C_{1-4} alkyl, C_{3-8} heterocycloalkyl or C_{3-8} heterocycloalkyl C_{1-4} alkyl; wherein any aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R_{1k} may be substituted by 1 to 5 groups selected from halogen, C_{1-6} alkyl, C_{1-6} alkoxy and halo substituted- C_{1-6} alkyl or $-C_{1-6}$ alkoxy;

R_{2k} is H, C_{1-6} alkyl, halo substituted C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl; and

each of R_{3k} or R_{4k} , independently, is H, halogen, OH, C_{1-6} alkyl, C_{1-6} alkoxy or halo substituted C_{1-6} alkyl or C_{1-6} alkoxy;

and the N-oxide derivatives thereof or prodrugs thereof, or a pharmacologically acceptable salt, solvate or hydrate thereof.

The compounds of formulae I to IXb may exist in free or salt form. Examples of pharmaceutically acceptable salts of the compounds of the formulae I to VI include salts with inorganic acids, such as hydrochloride, hydrobromide and sulfate, salts with organic acids, such as acetate, fumarate, maleate, benzoate, citrate, malate, methanesulfonate and benzenesulfonate salts, or, when appropriate, salts with metals such as sodium, potassium, calcium and aluminium, salts with amines, such as triethylamine and salts with dibasic amino acids, such as lysine. The compounds and salts of the combination of the present invention encompass hydrate and solvate forms.

Acyl as indicated above may be a residue R_y-CO- wherein R_y is C_{1-6} alkyl, C_{3-6} cycloalkyl, phenyl or phenyl- C_{1-4} alkyl. Unless otherwise stated, alkyl, alkoxy, alkenyl or alkynyl may be straight or branched.

Aryl may be phenyl or naphthyl, preferably phenyl.

When in the compounds of formula I the carbon chain as R_1 is substituted, it is preferably substituted by halogen, nitro, amino, hydroxy or carboxy. When the carbon chain is interrupted by an optionally substituted phenylene, the carbon chain is preferably unsubstituted. When the phenylene moiety is substituted, it is preferably substituted by halogen, nitro, amino, methoxy, hydroxy or carboxy.


Preferred compounds of formula I are those wherein R_1 is C_{13-20} alkyl, optionally substituted by nitro, halogen, amino, hydroxy or carboxy, and, more preferably those wherein R_1 is phenylalkyl substituted by C_{6-14} alkyl chain optionally substituted by halogen and the alkyl moiety is a C_{1-6} alkyl optionally substituted by hydroxy. More preferably, R_1 is phenyl- C_{1-6} alkyl substituted on the phenyl by a straight or branched, preferably straight, C_{6-14} alkyl chain. The C_{6-14} alkyl chain may be in ortho, meta or para, preferably in para.

Preferably each of R_2 to R_5 is H.

In the above formula of V "heterocyclic group" represents a 5- to 7 membered heterocyclic group having 1 to 3 heteroatoms selected from S, O and N. Examples of such heterocyclic groups include the heteroaryl groups indicated above, and heterocyclic compounds corresponding to partially or completely hydrogenated heteroaryl groups, e.g. furyl, thienyl, pyrrolyl, azepinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3-oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyranyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, pyrrolyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl or pyrazolidinyl. Preferred heterocyclic groups are 5- or 6-membered heteroaryl groups and the most pre-

8

A preferred compound of formula I is 2-amino-2-tetradecyl-1,3-propanediol. A particularly preferred S1P receptor agonist of formula I is FTY720, i.e. 2-amino-2-[2-(4-ocetylphenyl)ethyl]propane-1,3-diol in free form or in a pharmaceutically acceptable salt form (referred to hereinafter as Compound A), e.g. the hydrochloride salt, as shown:



A preferred compound of formula II is the one wherein each of R'_2 to R'_5 is H and m is 4, i.e. 2-amino-2-[2-[4-(1-oxo-5-phenylpentyl)phenyl]ethyl]propane-1,3-diol, in free form or in pharmaceutically acceptable salt form (referred to hereinafter as Compound B), e.g. the hydrochloride.

A preferred compound of formula III is the one wherein W is CH_3 , each of R''_1 to R''_3 is H, Z_2 is ethylene, X is heptyloxy and Y is H, i.e. 2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol, in free form or in pharmaceutically acceptable salt form (referred to hereinafter as Compound C), e.g. the hydrochloride. The R-enantiomer is particularly preferred.

Compounds may be in phosphorylated form. A preferred compound of formula IVa is the FTY720-phosphate (R_{2a} is H, R_{3a} is OH, X_a is O, R_{1a} and R_{1b} are OH). A preferred compound of formula IVb is the Compound C-phosphate (R_{2a} is H, R_{3b} is OH, X_a is O, R_{1a} and R_{1b} are OH, Y_a is O and R_{4a} is heptyl). A preferred compound of formula V is Compound B-phosphate.

A preferred compound of formula VI is (2R)-2-amino-4-[3-(4-cyclohexyloxybutyl)-benzo[b]thien-6-yl]-2-methylbutan-1-ol.

A preferred compound of formula IXa is e.g. 1-[4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidine-3-carboxylic acid, or a prodrug thereof.

S1P receptor agonists or modulators are known as having immunosuppressive properties or anti-angiogenic properties in the treatment of tumors, e.g. as disclosed in EP627406A1, WO 04/103306, WO 05/000833, WO 05/103309, WO 05/113330 or WO 03/097028.

Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system with chronic inflammatory demyelination leading to progressive decline of motor and sensory functions and permanent disability. The therapy of multiple sclerosis is only partially effective, and in most cases only offers a short delay in disease progression despite anti-inflammatory and immunosuppressive treatment. Accordingly, there is a need for agents which are effective in the inhibition or treatment of demyelinating diseases, e.g. multiple sclerosis or Guillain-Barré syndrome, including reduction of, alleviation of, stabilization of or relief from the symptoms which affect the organism.

Characteristic pathological features of demyelinating diseases include inflammation, demyelination and axonal and oligodendrocyte loss. In addition lesions can also have a significant vascular component. A firm link has recently been established between chronic inflammation and angiogenesis and neovascularization seems to have a significant role in the progression of disease.

It has now been found that S1P receptor modulators have

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.